YHLO COVID-19 Rapid Test Effectively Detect More Mutant Strains
Recently, the BA.5 and BA.4 variants of the Omicron subtype have spread rapidly in many countries and areas worldwide. The experts have analysed that due to the mutation of the SARS-CoV-2 spike protein again, the BA.4 and BA.5 variants are able to evade human immunity, which can lead to infection or reinfection of "almost everyone", including people who have been vaccinated or who have been cured from SARS-CoV-2.
Through antibody epitope analysis and verification of clinical samples or virus strains, it is concluded that the detection ability of YHLO COVID-19 Rapid Antigen Test Kits is not affected by variant strains BA.1, BA.2, BA.4 and BA.5. The above variant strains can be effectively detected while ensuring the sensitivity.
As the SARS-CoV-2 spike protein mutates constantly, YHLO chose to detect the N protein when developing the COVID-19 antigen detection kit, which is not easily mutated. Chinese Expert Consensus on Rapid Antigen Detection of SARS-CoV-2 in 2022 has pointed out that due to the large number of N protein synthesis, multiple specific antigenic determinants and high stability, N protein is an ideal antigen detection target, which can ensure high detection sensitivity, specificity and high tolerance to variant strains.
As a leading IVD company in China, based on proven technology platforms and systematic R&D solutions, YHLO is committed to the research and development of SARS-CoV-2 test kits since the outbreak of COVID-19. YHLO has successively launched IgM and IgG antibody test kits, antigen test kits, neutralizing antibody test kits and more. Up to the end of May 2022, YHLO products are widely used in more than 100 countries around the world, and over 400 scientific articles have been published using YHLO SARS-CoV-2 test kits.
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
